ESTRO 2025 - Abstract Book

S1310

Clinical - Lung

ESTRO 2025

The patient subgroup receiving Durvalumab had a statistical trend towards longer OS compared to the patient subgroup without Durvalumab [median OS: 43.8 months (95% CI NA) vs 27.2 months (21.7-32.8); HR: 0.64 (0.40-1.03), p =0.066; Figure 2].

Neither an increased number of cycles of chemotherapy nor Durvalumab statistically significantly increased toxicity. The incidence of early toxicity was 73.0% in patients having received 1-4 cycles of chemotherapy versus 83.1% in the 5-7 cycles group ( p =0.13), whereas late toxicity was 100% versus 92.0% ( p =0.14), respectively. The incidence of early toxicity was 81.0% in the Durvalumab-treated cohort versus 80.6% in the remaining patients ( p =0.56), and late toxicity was 94.2% and 93.3% ( p =0.57), respectively. Conclusion: Our data suggest that the administration of 5-7 cycles of chemotherapy significantly improves overall survival in LA NSCLC patients without increasing early or late toxicity. While the addition of Durvalumab showed a trend towards improved overall survival, it did not reach statistical significance. These findings on median survival-rates with durvalumab in a real-life cohort are in line with the randomized PACIFIC trial [1]. References: [1] Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes with Durvalumab after Chemoradiotherapy in Unresectable Stage III NSCLC: The PACIFIC Trial. Journal of Clinical Oncology. 2022; 40(12):1301-1311. DOI: 10.1200/JCO.21.01294. [2] Ulas, Ezgi B, and Idris Bahce. “Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?” Translational lung cancer research vol. 12,7 (2023): 1369-1371. doi:10.21037/tlcr-23 323 Keywords: NSCLC, adjuvant immunotherapy, outcome